EUVIMEDEUVIMED entdecken
Crossref

Immunocytochemical Analysis of Stem Cell Markers in Pancreatic Adenocarcinoma

Rabeah Al-Temaimi iD, Ali Al-Ali, Bency John, Kusum Kapila iD

Cytopathology · 2026

DOI: 10.1111/cyt.70072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytopathology, 2026. Verfasst von Rabeah Al-Temaimi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, College of Medicine, Kuwait University, Jabriya, Kuwait. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Biomarkers, Tumor, Adenocarcinoma, Neoplastic Stem Cells. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Kuwait University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic adenocarcinoma (PDAC) arises from transformed pancreatic stem cells. Different stemness pathways are thought to be involved in the progression of PDAC.

Objective

To assess the expression of four stem cell markers to determine the best candidate for targeted therapy.

Methods

Seventy‐one PDAC cell blocks were immunoassayed for CD24, OCT4, DCLK1 and CD44 expression and genotyped for common KRAS mutations.

Results

OCT4 was detected in 82.9% of PDAC and undetected in healthy pancreas. CD24 was detected in 23.9% of PDACs, while DCLK1 and CD44 were detected in 25.7% and 34.8% of PDACs, respectively. CD24 localisation was primarily nuclear in PDAC and membranous in healthy pancreas tissues. OCT4 expression and nuclear localisation correlated positively with CD24 expression and nuclear localisation ( r = 0.264, p = 0.023; r = 0.238, p = 0.041, respectively). OCT4 expression was lower in KRAS mutation‐positive specimens (β −0.54, 95% CI: −0.37 – (−0.088), p = 0.002).

Conclusion

OCT4 expression is a specific biomarker for PDAC. Its increased expression signified PDAC progression and CD24 activation in a subset of PDAC. KRAS mutants have lower OCT4 expression, suggesting an alternative mechanism for cancer progression than that in OCT4 positive PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsBiomarkers, TumorAdenocarcinomaNeoplastic Stem CellsCarcinoma, Pancreatic DuctalHumansCD24 AntigenHyaluronan ReceptorsOctamer Transcription Factor-3Proto-Oncogene Proteins p21(ras)ImmunohistochemistryProtein Serine-Threonine KinasesDoublecortin-Like KinasesMutationIntracellular Signaling Peptides and ProteinsFemaleMalePancreas

Stichwörter der Autor:innen

CD24CD44DCLK1OCT4biomarkerspancreatic cancer

Substanzen

Biomarkers, TumorCD24 AntigenHyaluronan ReceptorsKRAS protein, humanOctamer Transcription Factor-3Proto-Oncogene Proteins p21(ras)Protein Serine-Threonine KinasesPOU5F1 protein, humanCD24 protein, humanDCLK1 protein, human

Autor:innen und Institutionen

  • Department of Pathology, College of Medicine, Kuwait University, Jabriya, Kuwait.
  • Department of Medicine, College of Medicine, Kuwait University, Jabriya, Kuwait.
  • Department of Gastroenterology and Hepatology, Mubarak Al Kabeer Hospital, Jabriya, Kuwait.
  • Department of Laboratory Medicine, Mubarak Al Kabeer Hospital, Jabriya, Kuwait.

ORCID-Profile: Rabeah Al-Temaimi, Kusum Kapila

Förderung

  • Kuwait University

Zitieren

APA

Al-Temaimi, R., Al-Ali, A., John, B., & Kapila, K. (2026). Immunocytochemical Analysis of Stem Cell Markers in Pancreatic Adenocarcinoma. Cytopathology. https://doi.org/10.1111/cyt.70072

Vancouver

Al-Temaimi R, Al-Ali A, John B, Kapila K. Immunocytochemical Analysis of Stem Cell Markers in Pancreatic Adenocarcinoma. Cytopathology. 2026. doi:10.1111/cyt.70072

BibTeX
@article{AlTemaimi2026,
  author = {Al-Temaimi, Rabeah and Al-Ali, Ali and John, Bency and Kapila, Kusum},
  title = {Immunocytochemical Analysis of Stem Cell Markers in Pancreatic Adenocarcinoma},
  journal = {Cytopathology},
  year = {2026},
  doi = {10.1111/cyt.70072}
}
Kostenlos starten →